HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Affordable Care Act implementation looms amid hope, speculation
-
- Afinitor fails to meet survival endpoint for liver cancer indication
- AMA recommends physicians report, update conflicts of interest, disclosures
- ASH presents Dameshek Prize
- Center appoints associate director
- Long-term use of calcium-channel blockers may raise breast cancer risk
- Research group appoints vice chair
- FDA, EMA grant orphan drug status to CGTG-102 for soft tissue sarcoma
- Tamoxifen reduced contralateral breast cancer risk in patients with BRCA mutations
-
- Anemia increased risk for dementia in older adults
- miR-155 offers prognostic value in MBL, CLL
- HPV vaccination coverage unchanged among adolescent girls
- Exposure to particulate air matter pollution associated with lung cancer
- Maternal preventive care use increased HPV vaccination rates in boys
- Advanced treatments increased among prostate cancer patients least likely to benefit
- AIB1 expression predicted response to tamoxifen treatment in postmenopausal women
- Apixaban appears as effective as conventional therapy for acute VTE
-
- Aspirin use reduced BRAF wild-type colorectal cancer risk
- Bisphosphonate use may protect against colorectal cancer
- Careful patient selection should guide use of combination regimen for myeloma
- Combined enalapril, carvedilol may benefit patients with malignant hemopathies
- Insulin glargine vs. NPH did not increase risk for cancer
- Long-term intelligence declined in ALL survivors treated with cranial radiation
- Low-dose brachytherapy effectively treated facial mycosis fungoides lesions
- Maintenance sunitinib extends OS in metastatic pancreatic adenocarcinoma
-
- Maintenance therapy with bevacizumab plus pemetrexed improved PFS in advanced NSCLC
- Metastasis-free survival associated with OS in recurrent prostate cancer
- Patients experienced melanoma recurrence after 10 years or longer
- Prognostic risk factors identified for HPV-associated OSCC
- Retinoblastoma not linked solely to RB1 mutations, study finds
- Soy protein supplement failed to prevent prostate cancer recurrence
- Stage, tumor size predict survival in ovarian cancer
- Survival in epithelial ovarian cancer differed by BRCA mutation type
-
- TACE, sorafenib improve survival among patients with infiltrative HCC
- Topotecan may be therapeutic for Angelman, Prader-Willi syndrome
- Prevention treatment of herpes zoster pose challenges for patients with cancer Lisa K. Lohr, PharmD, BCPS, BCOP